| Name | Title | Contact Details |
|---|
The UroLift System is an FDA Cleared, revolutionary minimally invasive treatment of Benign Prostatic Hyperplasia (BPH) or an enlarged prostate.
DirectRx is an independent pharmacy dedicated to providing patients with unparalleled, personalized pharmaceutical care. At DirectRx Pharmacy, the patient, physician and pharmacy form a circle of integrated services and coordinated care. There are no gaps in patient care between physician and pharmacy, because we believe that collaboration and communication are critical to creating favorable treatment outcomes. Our sense of urgency and commitment to unparalleled customer care makes DirectRx unique in the marketplace. We are large enough to provide the full range of pharmaceutical solutions and medications required to optimally treat chronic disease states, yet small enough to care that each patient stays on their prescribed regimen and receives the support they need throughout the course of their treatment. We believe in innovative ideas. Breaking traditional methods, DirectRx has an integration of care between the patient and the provider including a support system for the patient, from help with financial assistance to expert advice on how to manage the complicated drug regimens. DirectRx is accredited by NABP, ACHC, URAC and WBENC. Unlike other pharmacies, DirectRx is owned and operated by certified doctors of pharmacy. As a family-owned business, the company has grown to serve more than 20 states since its inception more than two decades ago. Investments in technology help to provide clients with accurate, timely orders at competitive prices. DirectRx is led by founder and CEO Santa Zawaideh, R.Ph., who has been in private, independent practice since 1980. She is the proud recipient of the Michigan Pharmacist Association`s Governor`s Award and former two-term president of the Oakland County Pharmacy Association. Vice President of Clinical Services Amanda Berishaj, Pharm. D., daughter of Zawaideh, oversees the daily operations of DirectRx, as well as the clinical operations of patients with chronic disease states.
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company`s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.
Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company`s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.